BG
AST

Bellevue Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Bellevue Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,875
Closed -$9K – 139
2016
Q1 		$9K Buy
+1,875
New +$7.26K ﹤0.01% 129

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group's AST Position: Q2 2016 in Review

Bellevue Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2016, closing a stake of 1,875 shares — an estimated $9K sold.

Bellevue Group first reported a position in AST in Q1 2016 and held it in 1 quarter. The position peaked at $9K in Q1 2016. 66 funds tracked by Wall St. Rank hold AST as of Q2 2016.

  • Bellevue Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2016 after selling out during the quarter.
  • Bellevue Group sold 1,875 Asterias Biotherapeutics Inc. Series A shares in Q2 2016, an estimated $9K.
  • Bellevue Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2016 and held it in 1 quarter.
  • Bellevue Group's Asterias Biotherapeutics Inc. Series A position peaked at $9K in Q1 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2016.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.